Evidence map›Paper›PMID 34575165›Full record

ReviewJournal of clinical medicine2021

HBV and HDV: New Treatments on the Horizon.

Valentina Zuccaro, Erika Asperges, Marta Colaneri, Lea Nadia Marvulli, Raffaele Bruno

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Special Issue "New Therapies of Liver Diseases".Journal of clinical medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Valentina ZuccaroU.O.C. Malattie Infettive I Fondazione IRCCS Policlinico San Matteo-Università di Pavia, 27100 Pavia, Italy.ORCID 0000-0001-6433-506X
Erika AspergesU.O.C. Malattie Infettive I Fondazione IRCCS Policlinico San Matteo-Università di Pavia, 27100 Pavia, Italy.
Marta ColaneriU.O.C. Malattie Infettive I Fondazione IRCCS Policlinico San Matteo-Università di Pavia, 27100 Pavia, Italy.
Lea Nadia MarvulliU.O.C. Malattie Infettive I Fondazione IRCCS Policlinico San Matteo-Università di Pavia, 27100 Pavia, Italy.
Raffaele BrunoU.O.C. Malattie Infettive I Fondazione IRCCS Policlinico San Matteo-Università di Pavia, 27100 Pavia, Italy.ORCID 0000-0002-0235-9207
University of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the accumulating knowledge, chronic hepatitis B (CHB) and HDV infection represent a global health problem, and there are still several critical issues, which frequently remain uncovered. In this paper, we provided an overview of the current therapeutic options and summarized the investigational therapies in the pipeline. Furthermore, we discussed some critical issues such as a "functional cure" approach, the futility of long-term NA therapy and the relevance of understanding drug actions and safety of antivirals, especially in special populations.

Indexed as

antiviralsfunctional cureHBVHDVpharmacology

Identifiers

PMID34575165
PMCPMC8471459
OpenAlexW3198150529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.